Vanda Pharmaceuticals (VNDA) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.67% |
| Dec 31, 2025 | 29.62% |
| Sep 30, 2025 | 22.41% |
| Jun 30, 2025 | -24.74% |
| Mar 31, 2025 | -13.85% |
| Dec 31, 2024 | -18.66% |
| Sep 30, 2024 | 19.18% |
| Jun 30, 2024 | -30.76% |
| Mar 31, 2024 | 16.75% |
| Dec 31, 2023 | -185.99% |
| Sep 30, 2023 | 220.49% |
| Jun 30, 2023 | -16.68% |
| Mar 31, 2023 | 12.48% |
| Dec 31, 2022 | 50.94% |
| Sep 30, 2022 | -25.16% |
| Jun 30, 2022 | -8.30% |
| Mar 31, 2022 | 22.28% |
| Dec 31, 2021 | -26.52% |
| Sep 30, 2021 | -22.09% |
| Jun 30, 2021 | 0.88% |
| Mar 31, 2021 | 23.89% |
| Dec 31, 2020 | -0.04% |
| Sep 30, 2020 | -89.94% |
| Jun 30, 2020 | 14.33% |
| Mar 31, 2020 | 22.04% |
| Dec 31, 2019 | -34.08% |
| Sep 30, 2019 | -34.12% |
| Jun 30, 2019 | 19.76% |
| Mar 31, 2019 | -4.37% |
| Dec 31, 2018 | 14.91% |
| Sep 30, 2018 | -14.90% |
| Jun 30, 2018 | -71.85% |
| Mar 31, 2018 | 41.89% |
| Dec 31, 2017 | 21.91% |
| Sep 30, 2017 | -3.81% |
| Jun 30, 2017 | 15.53% |
| Mar 31, 2017 | -24.63% |
| Dec 31, 2016 | -22.53% |
| Sep 30, 2016 | -0.74% |
| Jun 30, 2016 | -48.76% |
| Mar 31, 2016 | -26.31% |
| Dec 31, 2015 | 15.64% |
| Sep 30, 2015 | 48.59% |